What is the Mechanism of Brukinsa? Unpacking Zanubrutinib's Targeted Action
•
4 min read
Zanubrutinib, sold under the brand name Brukinsa, is a highly selective inhibitor of Bruton's tyrosine kinase (BTK) that has been shown to offer superior efficacy and cardiac safety compared to first-generation BTK inhibitors in clinical trials. This targeted oral therapy addresses the core signaling pathways that drive the growth of malignant B-cells, representing a major advancement in the treatment of certain blood cancers. Understanding **what is the mechanism of Brukinsa** provides crucial insight into how this precision medicine combats cancer at a molecular level.
